Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of minimal tumor burden on antibody response to vaccination.
Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, Panageas K, Livingston PO. Kim SK, et al. Among authors: livingston po. Cancer Immunol Immunother. 2011 May;60(5):621-7. doi: 10.1007/s00262-011-0975-9. Epub 2011 Jan 26. Cancer Immunol Immunother. 2011. PMID: 21267719 Free PMC article.
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. doi: 10.1007/s00262-004-0598-5. Epub 2005 Feb 22. Cancer Immunol Immunother. 2005. PMID: 15726361 Free PMC article. Clinical Trial.
Antibody inducing polyvalent cancer vaccines.
Ragupathi G, Gathuru J, Livingston P. Ragupathi G, et al. Cancer Treat Res. 2005;123:157-80. doi: 10.1007/0-387-27545-2_7. Cancer Treat Res. 2005. PMID: 16211870 Review.
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. Slovin SF, et al. Cancer Immunol Immunother. 2007 Dec;56(12):1921-30. doi: 10.1007/s00262-007-0335-y. Epub 2007 Jul 10. Cancer Immunol Immunother. 2007. PMID: 17619878 Free PMC article. Clinical Trial.
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO. Ragupathi G, et al. Among authors: livingston po. Cancer Immunol Immunother. 2003 Oct;52(10):608-16. doi: 10.1007/s00262-003-0399-2. Epub 2003 Jun 17. Cancer Immunol Immunother. 2003. PMID: 12811527 Free PMC article.
Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Kagan E, Ragupathi G, Yi SS, Reis CA, Gildersleeve J, Kahne D, Clausen H, Danishefsky SJ, Livingston PO. Kagan E, et al. Among authors: livingston po. Cancer Immunol Immunother. 2005 May;54(5):424-30. doi: 10.1007/s00262-004-0584-y. Epub 2004 Dec 30. Cancer Immunol Immunother. 2005. PMID: 15625606 Free PMC article.
Cancer vaccines targeting carbohydrate antigens.
Livingston PO, Ragupathi G. Livingston PO, et al. Hum Vaccin. 2006 May-Jun;2(3):137-43. doi: 10.4161/hv.2941. Epub 2006 May 16. Hum Vaccin. 2006. PMID: 17012906
153 results